相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Circulating microRNAs: potential biomarkers for common malignancies
Samantha Khoury et al.
BIOMARKERS IN MEDICINE (2015)
Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer
T. F. Hansen et al.
BRITISH JOURNAL OF CANCER (2015)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Circulating microRNAs as novel prognosis biomarkers for head and neck squamous cell carcinoma
Bo Hou et al.
CANCER BIOLOGY & THERAPY (2015)
Molecular histology of lung cancer: From targets to treatments
Steven L. Wood et al.
CANCER TREATMENT REVIEWS (2015)
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Tony Mok et al.
CLINICAL CANCER RESEARCH (2015)
Proteomics in Cancer Biomarkers Discovery: Challenges and Applications
Reem M. Sallam
DISEASE MARKERS (2015)
Novel ALK inhibitors in clinical use and development
Chaitanya Iragavarapu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
microRNA-26a suppresses recruitment of macrophages by down-regulating macrophage colony-stimulating factor expression through the PI3K/Akt pathway in hepatocellular carcinoma
Zong-Tao Chai et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Circulating Tumor DNA Is Effective for the Detection of EGFR Mutation in Non-Small Cell Lung Cancer: A Meta-analysis
Mantang Qiu et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2015)
Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer
Kun Nie et al.
TUMOR BIOLOGY (2015)
Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis
Xun Yuan et al.
SCIENTIFIC REPORTS (2015)
Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays
Britta Weber et al.
BMC CANCER (2014)
MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET
Jian-Ya Zhou et al.
CANCER LETTERS (2014)
Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients
Shuai Wang et al.
CLINICA CHIMICA ACTA (2014)
Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma
Kimberley Jones et al.
CLINICAL CANCER RESEARCH (2014)
Circulating tumor cells as promising novel biomarkers in solid cancers
Evi S. Lianidou et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2014)
Predictive value of a serum-based proteomic test in non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors: a meta-analysis
Wei Sun et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
MicroRNAs in Non-small Cell Lung Cancer: Current Status and Future Therapeutic Promises
D. Cortinovis et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
Marzia Del Re et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2014)
Exploring microRNA-mediated alteration of EGFR signaling pathway in non-small cell lung cancer using an mRNA:miRNA regression model supported by target prediction databases
Fengfeng Wang et al.
GENOMICS (2014)
Strategies for modern biomarker and drug development in oncology
Alan D. Smith et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Differentially expressed microRNAs in the serum of cervical squamous cell carcinoma patients before and after surgery
Wen-Tao Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
Jian Zhang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
MicroRNA-mediated regulation of KRAS in cancer
Minlee Kim et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Nucleo-cytoplasmic transport as a therapeutic target of cancer
Giovanni Luca Gravina et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Selective inhibitors of nuclear export (SINE)- a novel class of anti-cancer agents
Kaushal Parikh et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Circulating miRNAs in cancer: from detection to therapy
Wen-Tao Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application
Xun Yuan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Gefitinib Treatment in EGFR Mutated Caucasian NSCLC Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
Jean-Yves Douillard et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial
Vanesa Gregorc et al.
LANCET ONCOLOGY (2014)
MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer
Bing Li et al.
LUNG CANCER (2014)
Development of a Highly Sensitive and Specific Method for Detection of Circulating Tumor Cells Harboring Somatic Mutations in Non-Small-Cell Lung Cancer Patients
Frank Breitenbuecher et al.
PLOS ONE (2014)
Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment
Antonio Marchetti et al.
PLOS ONE (2014)
Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis
Jie Luo et al.
SCIENTIFIC REPORTS (2014)
Clinical utility of circulating tumor Cells n ALK-positive non-small-cell lung cancer
Vincent Faugeroux et al.
FRONTIERS IN ONCOLOGY (2014)
Novel agents and strategies for overcoming EGFR TKIs resistance
Fei-Yu Niu et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2014)
Can Serum be Used for Analyzing the EGFR Mutation Status in Patients with Advanced Non-small Cell Lung Cancer?
Seung Tae Kim et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2013)
Determination of EGFR mutations in single cells microdissected from enriched lung tumor cells in peripheral blood
Ran Ran et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2013)
High Resolution Melting Analysis for Epidermal Growth Factor Receptor Mutations in Formalin-fixed Paraffin-embedded Tissue and Plasma Free DNA from Non-small Cell Lung Cancer Patients
Chang-Wen Jing et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2013)
Detection of Circulating Tumor Cells Harboring a Unique ALK Rearrangement in ALK-Positive Non-Small-Cell Lung Cancer
Emma Pailler et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies
Xiaoqing Liu et al.
JOURNAL OF CLINICAL PATHOLOGY (2013)
Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping
Hye-Ryoun Kim et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2013)
Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs
Aamir Ahmad et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Comparison of EGFR Signaling Pathway Somatic DNA Mutations Derived From Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology
Hui Zhang et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2013)
A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non-Small-Cell Lung Cancer
Thomas E. Stinchcombe et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528
Oliver Gautschi et al.
LUNG CANCER (2013)
A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation
Wallace Akerley et al.
LUNG CANCER (2013)
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Muhammed Murtaza et al.
NATURE (2013)
microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation
Yi Shen et al.
MEDICAL ONCOLOGY (2013)
Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients
Isolde Summerer et al.
RADIATION ONCOLOGY (2013)
Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I-IV Non-Small Cell Lung Cancer Patients
Xiao Zhao et al.
RESPIRATION (2013)
ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma
M. Ilie et al.
ANNALS OF ONCOLOGY (2012)
VeriStrat® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib
J. L. Kuiper et al.
BRITISH JOURNAL OF CANCER (2012)
SnapShot: Lung Cancer Models
Anna F. Farago et al.
CELL (2012)
Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non-Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
Elizabeth A. Punnoose et al.
CLINICAL CANCER RESEARCH (2012)
Detection of EGFR Somatic Mutations in Non-Small Cell Lung Cancer (NSCLC) Using a Novel Mutant-Enriched Liquidchip (MEL) Technology
Li Zhang et al.
CURRENT DRUG METABOLISM (2012)
Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer
Koichi Goto et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI
Zhen Huang et al.
THORACIC CANCER (2012)
Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas
Kazuya Taniguchi et al.
CLINICAL CANCER RESEARCH (2011)
Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer
K. B. Sriram et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer
Wolfram Brugger et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Serum Detection of Epidermal Growth Factor Receptor Gene Mutations Using Mutant-enriched Sequencing in Chinese Patients with Advanced Non-small Cell Lung Cancer
B. Jiang et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2011)
Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors
Marie Brevet et al.
LUNG CANCER (2011)
Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer
Guo Jian et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients
Der-An Tsao et al.
LUNG CANCER (2010)
VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
David P. Carbone et al.
LUNG CANCER (2010)
Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non-Small Cell Lung Cancer Patients
Tony K. F. Yung et al.
CLINICAL CANCER RESEARCH (2009)
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer
Yanan Kuang et al.
CLINICAL CANCER RESEARCH (2009)
Detection of' epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-celi lung cancer
Chen He et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer
Hua Bai et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer
Philip C. Mack et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours
Pasi A. Jaenne
LUNG CANCER (2008)
Detection of mutations in EGFR in circulating lung-cancer cells
Shyamala Maheswaran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
H. Kimura et al.
BRITISH JOURNAL OF CANCER (2007)
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: A multicohort cross-institutional study
Fumiko Taguchi et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
Fred R. Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
Jeffrey A. Engelman et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer
Hideharu Kimura et al.
CLINICAL CANCER RESEARCH (2006)
EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer
Hideharu Kimura et al.
JOURNAL OF THORACIC ONCOLOGY (2006)
Erlotinib in lung cancer - Molecular and clinical predictors of outcome
MS Tsao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
